Melatonin

Melatonin is a hormone produced naturally in the human pineal gland in response to darkness. It regulates the circadian rhythm — the biological clock that signals sleep onset — and its production declines with age and is suppressed by exposure to artificial light at night. As a food supplement, exogenous melatonin has become one of the most commercially significant sleep-onset actives in the EU and US markets, particularly within gummy formats where its sublingual-friendly, kid-style delivery sits well with consumer preference.

For private-label brands, the strategic complexity is regulatory. The EU permits melatonin as a food supplement at ≤1 mg per portion with two authorised health claims (sleep onset and jet lag). Above 1 mg per portion, classification typically shifts to medicinal product, and Member State authorisations are required individually. The US permits melatonin as a dietary supplement under DSHEA with no statutory dose ceiling, and consumer norms run from 1 mg to 10 mg. The same physical gummy formulation cannot move between EU and US markets without regulatory adaptation; DAT formulates EU gummies at ≤1 mg as the operational default unless project-specific Member State authorisation supports otherwise.

Origin and history

Melatonin was first isolated and characterised in 1958 by dermatologist Aaron Lerner at Yale, working from bovine pineal extracts in a study aimed at understanding skin pigmentation (melatonin's name derives from its early-observed lightening effect on amphibian skin). Its role in regulating circadian rhythm and sleep onset was established through the 1970s and 1980s. The characterisation of melatonin receptors (MT1, MT2) in the 1990s clarified the molecular basis of its action.

Commercial melatonin is produced by total chemical synthesis from indole and tryptamine precursors. The synthetic form is chemically identical to the endogenous hormone. Regulatory classification has evolved unevenly: the US classified melatonin as a dietary supplement under DSHEA (1994), while EU Member States have taken varied positions — some treating it as a food supplement at low dose, some as a medicinal product across all doses. The EFSA authorisation of the 1 mg sleep-onset claim in 2010 (codified in Reg. 432/2012) established a clearer EU food-supplement pathway, but Member State classifications still vary and remain a project-specific verification.

Scientific overview

Melatonin acts via two G-protein-coupled receptors (MT1 and MT2) expressed in the suprachiasmatic nucleus of the hypothalamus — the master circadian clock — and in peripheral tissues. Activation of these receptors shifts circadian phase, reduces nocturnal core body temperature, and promotes sleep onset. Plasma melatonin rises in response to darkness, peaks around 02:00–04:00, and declines toward morning; exposure to short-wavelength (blue) light suppresses endogenous melatonin production.

Exogenous oral melatonin has a short plasma half-life (30–50 minutes for immediate-release formulations) and is metabolised primarily by hepatic CYP1A2 to 6-sulphatoxymelatonin, excreted in urine. Onset of the sleep-promoting effect occurs roughly 30–60 minutes after oral intake. The EFSA NDA Panel's substantiation of the sleep-onset claim (2010, codified 2012) is based on randomised controlled trials demonstrating reduction in sleep-onset latency at 1 mg taken close to bedtime. The jet-lag claim is substantiated at 0.5 mg, with specific timing conditions related to travel direction and arrival.

For gummy formulation, melatonin is operationally one of the simplest actives — sub-milligram dosing, tasteless, heat-stable, soluble. The manufacturing decisions revolve around dose level (constrained by target market regulation), conditions-of-use disclosure on pack, and microencapsulation for extended-release positioning if required.

Melatonin is one of the most familiar and commercially understood sleep-onset actives across EU and US markets, and the gummy format suits its delivery profile particularly well — sublingual contact, fast onset, pleasant taste, and an evening-routine ritual that fits consumer behaviour. Sleep-positioned EU gummies typically include 1 mg melatonin per serving (the maximum food-supplement dose and the EFSA-authorised claim dose), paired with L-theanine, lemon balm, magnesium, or chamomile for a 'sleep & calm' stack. Jet-lag- positioned ranges run at 0.5 mg per serving. US sleep-aid gummies commonly run at 3–5 mg per serving under DSHEA, sometimes higher for adult ranges.

From a formulation standpoint, melatonin at sub-milligram doses has no measurable effect on gummy texture, taste, colour, or cook behaviour. The supply form is straightforward (synthetic USP/EP grade); accurate dose-uniformity at sub-milligram levels is managed via triturate dilution and standard mixing protocols. Microencapsulated extended-release forms are available for projects positioning around 'stay asleep' rather than 'fall asleep', though most consumer demand sits on the sleep-onset side.

For pack-copy, EU-market gummies must respect the dose ceiling (≤1 mg for sleep-onset positioning, 0.5 mg for jet lag) and include the conditions-of-use wording for the authorised claim ('close to bedtime'). Pregnancy, medication, and under-18 contraindications must be disclosed. US-market gummies operate under DSHEA structure- function rules. The same physical gummy formulation cannot move between EU and US markets without regulatory adaptation; DAT confirms Member State / market strategy per project before formula lock.